Forum Topic News
  • Conversation: FDA approves Abbott’s latest drug-eluting stent

    • May 24, 2018 12:21 PM BST
    • FDA approves Abbott’s latest drug-eluting stent

      Abbott (NYSE:ABT) said yesterday that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent.
      The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott.
      “We developed XIENCE Sierra so that physicians can more easily deliver the stent even in challenging cases,” Chuck Brynelsen, SVP of Abbott’s vascular unit, said in prepared remarks. “The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”
      Abbott won CE Mark clearance for Xience Sierra in October last year and regulatory approval in Japan earlier this year. The device has been used in more than 8 million people worldwide, Abbott touted.
      Read more: https://www.drugdeliverybusiness.com/fda-approves-abbotts-latest-drug-eluting-stent/

Add Reputation

Do you want to add reputation for this member by this post?

or cancel